Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies

Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis

(2016) Alison Cameron-Vendrig et al.   DIABETES

An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury

(2015) Madoka Ihara et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Drug-induced mitochondrial dysfunction and cardiotoxicity

(2015) Zoltán V Varga et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus

(2015) Liam M McCormick et al.   Cardiovascular Diabetology

Pre-Treatment With Glucagon-Like Peptide-1 Protects Against Ischemic Left Ventricular Dysfunction and Stunning Without a Detected Difference in Myocardial Substrate Utilization

(2015) Liam M. McCormick et al.   JACC-Cardiovascular Interventions

Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1

(2014) Sophie J Clarke et al.   Cardiovascular Diabetology

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

(2014) Charles Pyke et al.   ENDOCRINOLOGY

Cardioprotection for percutaneous coronary intervention — Reperfusion quality as well as quantity

(2014) Joel P. Giblett et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Anti-inflammatory effect of exendin-4 postconditioning during myocardial ischemia and reperfusion

(2014) Xianjin Du et al.   MOLECULAR BIOLOGY REPORTS

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

(2013) Louise E Robinson et al.   BMJ Open

A Pilot Study to Assess Whether Glucagon-Like Peptide-1 Protects the Heart From Ischemic Dysfunction and Attenuates Stunning After Coronary Balloon Occlusion in Humans

(2011) Philip A. Read et al.   Circulation-Cardiovascular Interventions

Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease

(2011) Philip A Read et al.   HEART

Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor

(2010) Kiwon Ban et al.   ENDOCRINOLOGY

Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial

(2010) Hans Erik Bøtker et al.   LANCET

Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study

(2009) Stephen P. Hoole et al.   CIRCULATION

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

(2009) M. H. Noyan-Ashraf et al.   DIABETES

Remote ischaemic pre-conditioning does not attenuate ischaemic left ventricular dysfunction in humans

(2009) Stephen P. Hoole et al.   EUROPEAN JOURNAL OF HEART FAILURE

Translation of remote ischaemic preconditioning into clinical practice

(2009) Rajesh K Kharbanda et al.   LANCET

GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP

(2008) Brian D. Green et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION